VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 3536 · 115th Congress

To require persons who undertake Federally funded research and development of drugs to enter into reasonable…

Full title

To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

7 cosponsors · 7 D

0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.

What it does: CRS summary · Introduced in House · Jul 28, 2017

This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.

Latest action (Aug 4, 2017): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Jul 28, 2017

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.